I can almost guarantee you that the Zacks and The Street negative hit pieces were "leaked" a day or two beforehand to favored clients, relatives and cronies, who reaped nice profits. This is a loophole never addressed by the SEC(they only concern themselves with parties that front run company inside information). Articles, both positive and negative, by The Street, Zacks and Seeking Alpha, are not monitored by the SEC, even though their press releases can be huge profit making opportunities for front runners.
and only down 12.9% from $2.24 high, despite Zacks and Feurstein's hatchet job. Snake Alan ridicules excess weight loss, while focusing on baseline weight loss and blatantly ignorant of the fact that the FDA's SPA specifically mentions EWL. It was evident that Alan did not read the SPA or study the Australian approval.
EWL is a valid measurement accepted by the FDA. Feurestein again said VBLOC failed the study which is patently misleading, as we know VBLOC was successful, but below super superiority, because of the placebo effect.
So Alan is saying that his law degree trumps all the medical knowledge of the Australian authorities that approved VBLOC?
Zacks had a #1 STRONG BUY for CYTK and it fell almost 50%! Their comments today were unusually biased and they are chasing for new customers. Alan Feurstein refused to give me credit in 2008-09 when I wrote him that Pfizer would buy Encysive, and replied with a sarcastic rant. FYI, PFE bought ENCY shortly after I wrote Alan.
In the 11/14 CC Knudson said the FDA would announce a panel meeting date by the end of 2013, and expected a 1st qtr 2014 panel meeting. It is a long shot, but the FDA does not have to request an advisorty panel and has occasionally skipped a panel and gone directly to a decision.
It is becoming more and more evident that VBLOC would be a great boost for Medtronic as their stents face headwinds
Cardiac stents lose out in two new studies that conclude bypass surgery and drugs are better or equal options in helping to prevent future heart attacks from happening, at least for patients with stable heart disease. Such a finding could trigger lower stent use down the line--bad news for Abbott ($ABT), Medtronic ($MDT), Boston scientific ($BSX) and other manufacturers that continue to face a stagnant market for the devices.
Both studies are published in the journal JAMA Internal Medicine, and the Boston Globe highlighted the key results.
The press coverage has barely started. I laugh at Zacks "Sell' rating for ETRM. They once had a "STRONG BUY" rating on CYTK which is almost 50% since that rating. I sold my CYTK the day of the 1-6 R/S, made a few thousand and happily flipped to ETRM.
Despite down day Barrons showed $475,004 positive accumulation today. I've put many of the bashers on ignore, but I will address the screed about "how come no CC?" Answer: In the late stages of an approval process most companies do not want to have a CC whereby analysts badger for opinions of likelihood of approval. The FDA frowns on any perceived lobbying by a company having an application under late stage review.
It is common for next-day profit taking followed by another strong move up. Just a rumor of a partnership or buyout could double the stock price. Also, Euro news is due on whether additional CE marks are conferred for diabetes and hypertension.
Last chance for new entrants to get in cheap. Knudson told us on 11/14 that a press release announcing 18-month data would happen AFTER said info was sent to the FDA. Knudson also expected the FDA to announce an advisory committee date BEFORE the end of the year. That could happen any day now; a long shot, but it has happened before, is that the FDA says a panel meeting is not necessary, as the new info clears up previous questions. The FDA works closely with their Australian counterpart and is well aware of how Enteromedics gained approval there.
Isaac: You're the phony, co-opting the name of a famous writer. Get YOUR own 15 minutes of fame. I have been a Yahoo member for years under only one ID.
Are you trying to make a coherent thought? At the moment I am up $20,000 on ETRM by flipping CYTK the day of the R/S and avoiding a future $10,000 loss.
The bears will try an early raid tomorrow, but upward momentum is in the cards. My 22,000 shares @ 1.19 look awfully pleasing.
LOL, Penny Dreadful is now cleaning toilets at the basher boileroom where he#$%$ worked!